placed with approved registered firms including Hamdard Dawakhana. Organolyptic test is adopted for testing the quality of Unani medicines.

Representations for inclusion of drugs

1632. SHRI H. HANUMANTHAPPA: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 682 given in the Rajya Sabha on 24th July, 1989 and state:

(a) what is the name of the manufacturer who submitted representations for inclusion of 41 drugs;

(b) what are the names of 41 drugs and what are the basis and grounds given for their inclusion;

(c) what is the number and names of drugs for which Chairman of Committee received representations for inclusion under price control;

(d) whether it is a fact that Kelkar Committee did not discuss about all the drugs in their Supplementary Report;

(e) if so, what are the reasons therefor;

(f) whether it is a fact that remaining seven drugs do not fulfil any exclusion criteria;

(g) if so, what were the points on which the members were not unanimous;

(h) whether it is a fact that Kelkar Committee opined that Oxyphenyl-butazone and phenylbutazone are dangerous drugs; and

(i) if so, what are the basis for such opinion and also exempting these drugs from price control despite these facts?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) and (b) In its Supplementary Report, the Kelkar Committee did not mention the name of the manufacturer as well as the names of 41 bulk drugs. However, the issue has been discussed in detail in the Supplementary Report, of the Kelkar Committee copies of which are available in the Parliamentary Library.

(c) to (e) The Kelkar Committee applied the exclusion principles on a basket of drugs which was worked out by the Committee on the basis of the WHO list and a supplementary list relevant to Indian requirement.

(f) and (g) This has been discussed in the Supplementary Report of the Kelkar Committee, copies of which are available in the Parliament Library.

(h) and (i) The reasons for doing so are explained in the Kelkar Committee Report, copies of which are available in the Parliament Library.

MAPE enjoyed by M|s. Infar

1633. SHRI MOHD. KHALEELUR RAHMAN: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 2853 given in the Rajya Sabha on the 5th December, 1989 and state:

(a) when his Ministry directed M|s. Infar to furnish details regarding overcharging the price of Dexatopic Cream and when were the details received by his Ministry;

(b) whether his Ministry has worked out the unintended benefit made by the company;

(c) if so, what is the total amount due the period for which amount was overcharged from the consumer and the rate of recovery on each unit;

(d) whether it is a fact that the prices of most of their products are very high;

(e) whether it is a fact that the company is enjoying MAPE on a number of their products between 150 per cent to 300 per cent;

(f) if so, what are the names of those prices decontrolled medicines and MAPE enjoyed on each; and